Diligence memo · auto-generated · as of July 2, 2026
Cytogel Pharma, LLC
Cytogel Pharma, LLC looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Cytogel Pharma, LLC operates in Pharmaceuticals, based in DARIEN.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cytogel Pharma, LLC has raised $25M in disclosed capital across 9 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $16M on 2025-12-23.
Most recent recorded round closed around 2026-03-26.
Valuation (modeled)modeled
Provath models Cytogel Pharma, LLC at approximately $56M (range $34M–$73M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.51× the median modeled value of Series B Pharmaceuticals companies in 2025–2027 (17 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 14 months.
Last raise 3 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 69% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 45% of those peers.
Closest niche peers: Phlow Corp., AlphaTON Capital Corp, Triton Therapeutics, Inc., Sensorium Therapeutics, Inc., Belhaven Biopharma Inc..
Peoplefiled
19 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.